VEL-0230: Preliminary Phase I data

Preliminary data from the single-blind, placebo-controlled, U.S. Phase I trial (V101) in 30 healthy volunteers showed that oral VEL-0230 reduced CTx levels by 80% within 15 minutes. CTx is a biomarker...